ChromaDex Corporation (CDXC) News & Overview - Discounting Cash Flows
CDXC
ChromaDex Corporation
CDXC (NASDAQ)

CDXC's Business Model

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.
Sector & Industry Healthcare / Biotechnology
Website https://www.chromadex.com
CEO (Chief Executive Officer) Frank Louis Jaksch Jr.
Number of Employees
IPO date June 25, 2008

CDXC Latest News

Contact
CountryUS
Address10900 Wilshire Boulevard
CityLos Angeles
StateCA
Phone310 388 6706
Zip Code90024
Other Identifiers
CIK0001386570
ISINUS1710774076
CUSIP171077407
Open7.91
Previous Close7.94
Volume541.7 Thou.
Average Volume809.4 Thou.
Day’s Range7.745 – 7.92
52 Week Range2.305-9.18
MA (50)6.3384
MA (200)4.81478
Market Cap611.9 Mil.
Shares Out.77.75 Mil.
Earnings DateMay 06, 2025
Beta
Last Dividend
EPS
PE

Industry Competitors for CDXC

discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us
Want to become our sponsor?
Check out our Affiliate Program